Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Application

Liquid biopsies have been used to test for resistance mutations in some reports [1, 2]; however, it has not been applied currently within routine clinical practice. Liquid biopsy may be particularly useful if biopsies or re-biopsies cannot be performed, if the original biopsy is old, if there are concerns about material degradation, or when RNA testing cannot be done with blood samples. Finally, liquid biopsies can potentially be used to analyse circulating tumour DNA over the course of management of TRK fusion cancers [3]. 

References

  1. Hofman P. Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology. Cancers (Basel) 2017; 9: pii: E154. doi: 110.3390/cancers9110154.
  2. Russo M, Misale S, Wei G et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discov 2016; 6: 36-44.
  3. Wan JCM, Massie C, Garcia-Corbacho J et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017; 17: 223-238.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings